CL-14

CL-14

Cat.No.: CSC-C0514

Species: Homo sapiens (Human)

Source: Intestine; Colon

Morphology: strongly adherent epitheloid cells growing in monolayers and forming islets

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0514
Description
Established from a male patient with a well-differentiated primary sigmoid adenocarcinoma of TNM stage T3N0M0
Species
Homo sapiens (Human)
Source
Intestine; Colon
Recommended Medium
Culture Properties
monolayer
Morphology
strongly adherent epitheloid cells growing in monolayers and forming islets
Karyotype
Human flat-moded hypotetraploid karyotype with 3.5% polyploidy - 78-85<4n>XX, -Y, -Y, -3, -3, -4, -4, +5, +5, +6, -8, +9, +9, -10, -10, +11, -13, -14, -16, -16, -17, -18, -18, -18, -21, -21, -21, -22, +6-12mar, del(1)(p32)x2, i(5p)x3, add(14)(p11)x2, add(
Reference
Disease
Colon Adenocarcinoma
Quality Control
Mycoplasma: negative in microbiological culture, PCR assays
Immunology: cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin -
Viruses: PCR:
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 1 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
CL14
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The CL-14 cell line is a human colorectal adenocarcinoma cell line developed from the main tumor of the sigmoid colon of a male patient with a well-differentiated adenocarcinoma (TNM stage T3N0M0). Morphologically it grows as highly adherent epithelial cells creating compact islets or monolayers. It has a hypotetraploid karyotype (modal number 78-85) with homozygous TP53 mutation (p.Arg273Cys). This is an EBV-negative and microsatellite-stable (MSS) line.

CL-14 is well characterized for its very high vulnerability to SARS-CoV and SARS-CoV-2 infection, which makes it an important model for coronavirus entry and antiviral studies. It is also used for chemosensitivity profiling, drug metabolism assays, and studies of Wnt/β-catenin and p53 pathway changes in gastrointestinal malignancies in colorectal cancer research. Culturally, CL-14 needs to be a 1:1 mixture of DMEM and Ham's F12 with serum, and incubated at 37°C with 5% CO2. Cells are slow-growing (doubling time ~1 week) and can be difficult to detach, hence it is advised to use prolonged trypsin/EDTA treatment and avoid mechanical scraping.

Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer

Oncogene | DOI | Paper |

Background

Whole-genome and transcriptome sequencing of colorectal cancer identified a recurrent tumor-specific LACTB2-NCOA2 fusion from chromosome 8 rearrangement. The fusion transcript occurred in 6/99 CRC cases and lacked functional domains, suggesting an amorphic rearrangement. NCOA2 was downregulated in CRC. Wild-type NCOA2 suppressed proliferation, colony formation, migration, invasion, and tumor growth, while the fusion protein did not. NCOA2 inhibited Wnt/β-catenin signaling by upregulating inhibitors and downregulating stimulators. The study proposes NCOA2 as a negative growth regulator disrupted by LACTB2 fusion.

Key Findings

The study identified a tumor-specific LACTB2-NCOA2 fusion caused by intrachromosomal rearrangement of chromosome 8, detected at DNA and RNA levels. It was recurrent in 6/99 (6.1%) colorectal cancer cases and absent in matched normal tissues. The fusion transcript encodes truncated non-domain fragments, indicating loss-of-function/amorphic rearrangement. NCOA2, but not LACTB2, was significantly downregulated in CRC tissues and cell lines. Functional assays showed wild-type NCOA2, but not the LACTB2-NCOA2 fusion, inhibited CRC cell proliferation, colony formation, migration and invasion, induced apoptosis, and suppressed xenograft growth. NCOA2 knockdown in normal colonocytes increased proliferation and reduced apoptosis. Mechanistically, wild-type NCOA2 repressed Wnt/β-catenin signaling by upregulating inhibitors such as APC and Frzb and downregulating stimulators such as Frizzled, Dishevelled and CK1, while the fusion protein had negligible effects. These findings establish NCOA2 as a negative growth regulator in CRC and demonstrate a novel mechanism of tumor suppressor disruption by recurrent in-frame fusion.

Contribution

Creative Bioarray provided the authenticated human colon cancer cell line CL-14, which was included in the CRC cell line panel. This cell line supported the study's demonstration of NCOA2 downregulation in colorectal cancer cells. Beyond supplying CL-14, Creative Bioarray had no other reported role in the study.

Tumor-suppressing functions of NCOA2 and their abrogation after fusion with LACTB2
Fig. 1. Tumor-suppressing functions of NCOA2 and their abrogation after fusion with LACTB2

ACE2/TMPRSS2 Expression is Insufficient to Predict SARS-CoV-2 Permissiveness

To systematically identify robust cellular models for SARS-CoV-2 infection, researchers screened the Cancer Cell Line Encyclopedia (CCLE) RNA-seq database for expression of the receptor ACE2and priming protease TMPRSS2, followed by rigorous experimental validation of viral permissiveness in vitro. Though these two factors are canonical mediators of viral entry, their sufficiency and the possible involvement of alternative receptors are still discussed. In order to better understand the correlation between receptor expression and actual infection outcome, the study defined permissiveness as the ability of a host cell to support the complete viral replication cycle and the release of mature virions.

Experimental infection with wild-type SARS-CoV-2 across the screened panel showed remarkable discordance between receptor expression and viral replication. Unexpectedly, most cell lines (15 of 29) failed to support detectable virus replication in spite of expressing both ACE2and TMPRSS2 (Fig. 1A). An additional 11 lines gave rise to infectious titers which never exceeded the input inoculum. Only 3 cell lines, i.e. the colon carcinoma lines CL-14 and CL-40 and the breast carcinoma line CAL-51, were found to be highly permissive with an increase of 2 to 500-fold in the initial viral load at 1-4 days post infection (dpi). The infectious titers obtained in CL-14 and CAL-51 were similar to those in gold-standard cell lines including the lung carcinoma CALU-3, colon carcinoma CACO-2 and African green monkey kidney VERO cells (Fig. 1B). Interestingly, CAL-51 and CACO-2 showed a steady increase of viral titers until day three while VERO cells and CL-14 peaked within 24 hours. The newly identified CL-40 line, expressing high levels of NRP1 in addition to ACE2and TMPRSS2 showed titers close to the inoculum level despite clear replication. These results underscore that ACE2and TMPRSS2expression alone is not sufficient for productive infection and reveal novel cell-type-specific replication kinetics in cancer cell lines.

Susceptibility of tumor cell lines toward SARS-CoV-2 infection.

Fig. 2. Susceptibility of tumor cell lines toward SARS-CoV-2 infection (Pommerenke C, Rand U, et al., 2021).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products